A fibromyalgia flare is a transient exacerbation of baseline fibromyalgia symptoms — characterized by intensified widespread pain, fatigue, cognitive dysfunction ("fibrofog"), and sleep disturbance — typically triggered by stress, overexertion, poor sleep, or weather changes. [1] Flares are distinguished from baseline symptoms by their greater severity, often described as "flu-like body aches and exhaustion". [1] The primary ED and primary care role is to exclude dangerous mimics, manage acute symptoms, and ensure appropriate follow-up.
1. History
- Pain characterization: Location (diffuse vs. focal), quality (deep aching, burning, throbbing), severity (0–10 scale), and comparison to baseline fibromyalgia symptoms
- Timing and triggers: Onset, duration of flare, identifiable precipitants — stress, physical overexertion ("overdoing it"), poor sleep, weather changes, illness, emotional trauma [1]
- Associated symptoms: Fatigue severity, sleep quality (unrefreshing sleep, insomnia), cognitive complaints (memory, concentration), mood changes (anxiety, depression), headache, IBS symptoms, paresthesias [2]
- Important negatives: Fever, weight loss, joint swelling/redness, rash, focal weakness, new neurologic deficits, chest pain — these suggest an alternative diagnosis [2]
- Medication history: Current fibromyalgia regimen, recent changes, adherence, recent addition of medications known to cause diffuse pain (statins, opioids, bisphosphonates, aromatase inhibitors) [2]
2. Alarm Features
- True joint swelling, erythema, or deformity → suggests inflammatory arthritis, not fibromyalgia [2]
- Fever, night sweats, unintentional weight loss → infection, malignancy, or systemic inflammatory disease [3]
- Focal neurologic deficits or progressive weakness → multiple sclerosis, myopathy, neuropathy [2]
- New-onset symptoms after age 50 → consider polymyalgia rheumatica, giant cell arteritis, malignancy [4]
- Elevated inflammatory markers (ESR, CRP) → fibromyalgia should have normal acute-phase reactants [4]
- Suicidal ideation → more than half of fibromyalgia patients have comorbid depression; screen actively [2]
3. Medications
- FDA-approved for fibromyalgia: Duloxetine (60 mg daily), milnacipran (50 mg BID), pregabalin (150–450 mg at bedtime) [2]
- Off-label with evidence: Amitriptyline (10–30 mg at bedtime), cyclobenzaprine (5–40 mg daily) [2]
- For acute flare symptom management:
- Optimize existing regimen; ensure adequate dosing and adherence [2]
- Cyclobenzaprine 5–10 mg at bedtime for short-term muscle pain/spasm relief [2]
- Low-dose tramadol may be considered if alternatives fail, though opioids are generally not recommended [5]
- Avoid/use with caution:
- Opioids — do not target central sensitization, risk of hyperalgesia, dependence; not recommended [2][6]
- NSAIDs — not superior to placebo for fibromyalgia pain per Cochrane review [2]
- Corticosteroids — no role in fibromyalgia; response to steroids suggests an alternative diagnosis
- TCAs in elderly (≥65) — potentially inappropriate due to anticholinergic effects [6]
- Medication interactions: SNRIs + tramadol → serotonin syndrome risk; pregabalin + CNS depressants → additive sedation
4. Diet
- Acute flare: Adequate hydration, avoidance of caffeine excess and alcohol (which worsen sleep quality)
- Dietary triggers to consider: Excitotoxins (MSG, aspartame), high-processed foods, gluten (in patients with non-celiac gluten sensitivity) [7-8]
- Long-term dietary strategies with emerging evidence:
- Mediterranean diet — associated with improvements in pain, fatigue, and cognitive symptoms [9]
- Low-FODMAP diet — may help patients with concurrent IBS symptoms [10]
- Weight management — obesity worsens pain, fatigue, and sleep quality in fibromyalgia [8]
- Supplements with preliminary evidence: Vitamin D, magnesium, omega-3 fatty acids, coenzyme Q10 — evidence remains limited and no standard guidelines exist [11-12]
5. Review of Systems
- Musculoskeletal: Widespread pain, stiffness, tenderness to touch
- Neurologic: Paresthesias, headache, cognitive dysfunction, dizziness
- Psychiatric: Depression, anxiety, panic attacks, PTSD symptoms
- Sleep: Insomnia, unrefreshing sleep, restless legs [2]
- GI: Abdominal pain, bloating, alternating bowel habits (IBS overlap) [2]
- GU: Pelvic pain, urinary urgency/frequency (interstitial cystitis overlap) [2]
- Constitutional: Fatigue (distinguish from fever/weight loss which are red flags)
- Autonomic: Orthostatic intolerance, palpitations, temperature sensitivity [13-14]
6. Collateral History and Family History
- Collateral: Baseline functional status, prior flare patterns and duration, current psychosocial stressors, recent life changes, sleep partner observations (snoring, apnea, restless legs)
- Family history: Fibromyalgia has familial aggregation; first-degree relatives have an 8-fold increased risk. Also screen for family history of autoimmune disease, mood disorders, and chronic pain conditions [15]
- Social context: Employment status, disability claims, social support, history of physical/sexual abuse or childhood trauma (associated with fibromyalgia development) [16]
7. Risk Factors
- Female sex (2–14× more commonly diagnosed than males) [2]
- Age — peak onset 20–50 years; unusual to present de novo after age 50 [4]
- Comorbid psychiatric disorders — depression (>50%), anxiety, PTSD [2]
- Chronic overlapping pain conditions — IBS, migraine, TMJ disorder, chronic fatigue syndrome, endometriosis [2]
- Obesity — worsens symptom severity [8]
- Physical or emotional trauma, including childhood abuse [16]
- Sedentary lifestyle [17]
- Coexisting inflammatory rheumatic disease — RA, ankylosing spondylitis, psoriatic arthritis [2]
- Sleep disorders — obstructive sleep apnea, restless legs syndrome [2]
8. Differential Diagnosis
The key principle: fibromyalgia flare is a clinical diagnosis of exclusion of new pathology in a patient with known fibromyalgia. The following must be considered: [2-4]
- Rheumatologic: Rheumatoid arthritis, SLE, polymyalgia rheumatica, spondyloarthropathy, polymyositis/dermatomyositis
- Endocrine: Hypothyroidism, hyperparathyroidism, adrenal insufficiency, vitamin D deficiency
- Infectious: Viral syndrome, Lyme disease, hepatitis, endocarditis
- Neurologic: Multiple sclerosis, small fiber neuropathy, myopathy [16]
- Medication-induced pain: Statins, opioid-induced hyperalgesia, bisphosphonates, aromatase inhibitors [2]
- Psychiatric: Major depressive disorder (somatic presentation), somatization disorder
- Oncologic: Occult malignancy with paraneoplastic symptoms (especially if new onset after 50) [4]
Distinguishing features of fibromyalgia: Diffuse soft tissue tenderness without joint swelling/inflammation, normal inflammatory markers, somatic symptom cluster (fatigue, fibrofog, unrefreshing sleep) [2][4]
9. Past Medical History
- Prior fibromyalgia diagnosis — confirm original diagnostic criteria used
- Previous flare frequency, severity, and what has worked in the past
- Comorbid chronic overlapping pain conditions (IBS, migraine, TMJ, interstitial cystitis) [2]
- Psychiatric history — depression, anxiety, PTSD, substance use [2]
- Surgical history — prior orthopedic or abdominal surgeries
- Sleep study results if available (OSA, restless legs)
- Medication trials — document what has been tried and failed
10. Physical Exam
- Vital signs: Generally normal; tachycardia may reflect pain/anxiety/autonomic dysfunction; fever is a red flag [14]
- General: Assess for distress, affect, psychomotor slowing
- Musculoskeletal: Diffuse soft tissue tenderness on palpation; no joint swelling, effusion, erythema, or deformity (if present, investigate alternative diagnosis) [2]
- Neurologic: Full neurologic exam — strength, sensation, reflexes, gait should be normal; focal deficits warrant further workup [2]
- Skin: No rash (malar rash → SLE; heliotrope → dermatomyositis)
- Thyroid: Palpate for goiter or nodules
- Focused maneuvers: Tender point examination is no longer required for diagnosis but may support clinical assessment [2]
11. Lab Studies
Fibromyalgia is a clinical diagnosis and labs are used to exclude mimics, not confirm the diagnosis: [2]
- Baseline screening (if not recently done):
- CBC — rule out anemia, hematologic malignancy
- CMP — renal/hepatic function, calcium (hyperparathyroidism)
- TSH — hypothyroidism
- ESR and/or CRP — should be normal in fibromyalgia; elevation suggests inflammatory or infectious etiology [2][4]
- Consider based on clinical suspicion:
- Vitamin D level — deficiency common and may worsen pain [18]
- CK — if myopathy suspected (proximal weakness)
- ANA, RF — only if clinical features suggest autoimmune disease; high false-positive rates in general population [2]
- HbA1c — if diabetic neuropathy suspected
- Not routinely recommended: Lyme titers without exposure history, extensive autoimmune panels without clinical indication [2]
12. Imaging
- Generally not indicated for fibromyalgia flare in a patient with established diagnosis and typical presentation
- Imaging should be pursued only if exam findings suggest an alternative diagnosis:
- Joint radiographs if swelling/deformity present
- MRI brain/spine if new neurologic deficits
- Chest X-ray if constitutional symptoms (fever, weight loss, cough)
- Avoid unnecessary imaging — promotes medicalization and does not change management in typical flares [19]
13. Special Tests
- Fibromyalgia Impact Questionnaire (FIQ): Validated tool to assess symptom severity and functional impact; useful for tracking flare severity over time [14]
- Widespread Pain Index (WPI) + Symptom Severity Scale (SSS): Components of the 2016 ACR diagnostic criteria (WPI ≥7 and SSS ≥5, or WPI 4–6 and SSS ≥9) [2][20]
- PHQ-9 / GAD-7: Screen for comorbid depression and anxiety
- Epworth Sleepiness Scale / STOP-BANG: If sleep disorder suspected
- FM/a Test: Cytokine-based blood test with 93% sensitivity and 89% specificity — expensive, not commonly used, but may help differentiate from rheumatologic conditions [2]
14. ECG
- Routine ECG is not necessary for fibromyalgia flare [21]
- Consider ECG if:
- Chest pain or palpitations are prominent
- Starting or adjusting medications with cardiac effects (TCAs, SNRIs)
- Autonomic symptoms (syncope, presyncope, orthostatic intolerance)
- Autonomic cardiovascular dysfunction is described in fibromyalgia — reduced heart rate variability, sympathetic predominance, blunted baroreflex sensitivity — but these are research findings, not routine clinical screening targets [14][22]
- The frontal QRS-T angle has been shown to be unchanged in fibromyalgia patients vs. controls, and duloxetine use does not alter it [21]
15. Assessment
- Fibromyalgia flare represents a transient worsening of central sensitization symptoms, typically self-limited over days to weeks [1]
- Severity stratification: Mild (manageable with self-care) → Moderate (functional impairment, needs medication adjustment) → Severe (unable to perform ADLs, psychiatric crisis)
- Typical presentation: Diffuse pain escalation with fatigue, cognitive dysfunction, and sleep disruption in a patient with known fibromyalgia, triggered by identifiable stressor
- Atypical features warranting further evaluation: Focal pain, joint swelling, fever, weight loss, new neurologic symptoms, elevated inflammatory markers
- Complications: Functional disability, medication overuse, opioid dependence, depression exacerbation, suicidality
16. Treatment Plan
Initial stabilization (ED/urgent care)
- Reassurance and validation — acknowledge the flare is real and distressing
- Address identifiable triggers (sleep deprivation, acute stressor)
- Non-pharmacologic: heat application, relaxation techniques, guided breathing
Pharmacologic management
- Optimize existing regimen — ensure adequate dosing of duloxetine (60 mg), pregabalin (up to 450 mg), or amitriptyline (20–30 mg) [2]
- For acute symptom relief: cyclobenzaprine 5–10 mg at bedtime [2]
- Melatonin 3–5 mg for sleep disruption during flare
- Acetaminophen for mild analgesic effect (limited evidence but low risk) [2]
- Avoid opioids and benzodiazepines [2][6]
Nonpharmacologic (cornerstone of management)
- Exercise: Aerobic exercise of moderate intensity is the strongest evidence-based nonpharmacologic intervention; start low, go slow during flare, then gradually resume [2][23]
- CBT: Moderate-quality evidence for improvement in pain and disability [2][24]
- Mind-body therapies: Yoga, tai chi, mindfulness-based stress reduction [2][25]
- Sleep hygiene: Consistent sleep-wake schedule, limit screens, cool dark room [25]
The EULAR stepwise treatment algorithm recommends starting with education and exercise, progressing to individualized pharmacologic and psychological interventions based on dominant symptoms: [26]
17. Disposition
- Discharge (vast majority): Typical flare in known fibromyalgia patient with normal vitals, no red flags, adequate pain control, and safe home environment
- Observation/admission considerations:
- Suicidal ideation or psychiatric emergency
- Inability to perform basic self-care
- Diagnostic uncertainty requiring urgent workup (e.g., concern for new autoimmune, infectious, or malignant process)
- Severe medication adverse effects
- Specialist consultation triggers:
- Rheumatology — if inflammatory markers elevated, joint swelling, or diagnostic uncertainty [2]
- Neurology — new focal deficits, suspected small fiber neuropathy [16]
- Psychiatry — refractory depression, suicidality, substance use disorder
- Pain medicine — refractory pain despite multimodal therapy
18. Follow Up / Return Precautions
- Follow-up timing: PCP or rheumatology within 1–2 weeks for medication adjustment and reassessment; sooner if symptoms worsen
- Return precautions — instruct patient to return for:
- Fever, new joint swelling or redness
- Progressive weakness or new numbness
- Unintentional weight loss
- Worsening depression or suicidal thoughts
- Symptoms not improving within 2–4 weeks
- Patient counseling:
- Flares are common and typically self-limited [1]
- Identify and modify triggers (stress management, pacing activities, sleep optimization)
- Regular low-impact exercise reduces flare frequency and severity [2]
- Avoid "boom-bust" activity patterns (overexertion followed by prolonged rest)
- Expected recovery: Most flares resolve within days to a few weeks with trigger modification and optimized management [1]
References
1. Fibromyalgia Flares: A Qualitative Analysis. — Vincent A, Whipple MO, Rhudy LM. Pain Medicine. 2016.
2. Fibromyalgia: Diagnosis and Management. — Winslow BT, Vandal C, Dang L. American Family Physician. 2023.
3. Diagnostic Confounders of Chronic Widespread Pain: Not Always Fibromyalgia. — Häuser W, Perrot S, Sommer C, Shir Y, Fitzcharles MA. Pain Reports. 2017.
4. Polymyalgia Rheumatica. — Dejaco C, Matteson EL. The New England Journal of Medicine. 2026.
5. Management of Fibromyalgia Syndrome. — Goldenberg DL, Burckhardt C, Crofford L. The Journal of the American Medical Association. 2004.
6. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. — Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 2022.
7. Fibromyalgia and Nutrition: What News?. — Rossi A, Di Lollo AC, Guzzo MP, et al. Clinical and Experimental Rheumatology. 2015.
8. Review of Nutritional Approaches to Fibromyalgia. — Kadayifci FZ, Bradley MJ, Onat AM, Shi HN, Zheng S. Nutrition Reviews. 2022.
9. Mediterranean Diet and Its Low-Antigenic and Anti-Inflammatory Properties on Fibromyalgia: A Systematic Review. — Miller EE, Jayakrishnan S, Froio F, et al. Clinical and Experimental Rheumatology. 2025.
10. Dietary Interventions in Fibromyalgia: A Systematic Review. — Silva AR, Bernardo A, Costa J, et al. Annals of Medicine. 2019.
11. Neuronutritional Approach to Fibromyalgia Management: A Narrative Review. — Badaeva A, Danilov A, Kosareva A, et al. Pain and Therapy. 2024.
12. Is the Gut Microbiome of Importance in Fibromyalgia? A Critical Review of Emerging Evidence. — Shtrozberg S, Bazzichi L, Sarzi-Puttini P, Aloush V, Ablin JN. Clinical and Experimental Rheumatology. 2025.
13. Autonomic Dysfunction in Fibromyalgia Syndrome: The Role of Small Fiber Damage. — Falco P, Leone CM, Galosi E, et al. Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology. 2026.
14. Coexistence of Fibromyalgia Syndrome and Inflammatory Rheumatic Diseases, and Autonomic Cardiovascular System Involvement in Fibromyalgia Syndrome. — Kocyigit BF, Akyol A. Clinical Rheumatology. 2023.
15. AAPT Diagnostic Criteria for Fibromyalgia. — Arnold LM, Bennett RM, Crofford LJ, et al. The Journal of Pain. 2019.
16. The Challenge of Differentiating Fibromyalgia From Small-Fiber Neuropathy in Clinical Practice. — Bailly F. Joint Bone Spine. 2021.
17. Mixed Exercise Training for Adults With Fibromyalgia. — Bidonde J, Busch AJ, Schachter CL, et al. The Cochrane Database of Systematic Reviews. 2019.
18. Fibromyalgia and Nutrition: Therapeutic Possibilities?. — Bjørklund G, Dadar M, Chirumbolo S, Aaseth J. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2018.
19. Nociplastic Pain: Towards an Understanding of Prevalent Pain Conditions. — Fitzcharles MA, Cohen SP, Clauw DJ, et al. Lancet. 2021.
20. 2016 Revisions to the 2010/2011 Fibromyalgia Diagnostic Criteria. — Wolfe F, Clauw DJ, Fitzcharles MA, et al. Seminars in Arthritis and Rheumatism. 2016.
21. Frontal QRS-T Angle Remains Unchanged in Fibromyalgia: A Cross-Sectional Study With Implications for Routine ECG Screening. — Tezcan H, Tezcan EA. Frontiers in Medicine. 2025.
22. Aberrances in Autonomic Cardiovascular Regulation in Fibromyalgia Syndrome and Their Relevance for Clinical Pain Reports. — Reyes Del Paso GA, Garrido S, Pulgar A, Martín-Vázquez M, Duschek S. Psychosomatic Medicine. 2010.
23. Efficacy of Nonpharmacological Interventions for Individual Features of Fibromyalgia: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. — Kundakci B, Kaur J, Goh SL, et al. Pain. 2022.
24. Management of Chronic Multisymptom Illness: Synopsis of the 2021 US Department of Veterans Affairs and US Department of Defense Clinical Practice Guideline. — Robbins R, Helmer D, Monahan P, et al. Mayo Clinic Proceedings. 2022.
25. International, Multidisciplinary Delphi Consensus Recommendations on Non-Pharmacological Interventions for Fibromyalgia. — Kundakci B, Hall M, Atzeni F, et al. Seminars in Arthritis and Rheumatism. 2022.
26. Fibromyalgia syndrome and myofascial pain syndromes. — Winfried Häuser, Mary‐Ann Fitzcharles Clinical Pain Management. 2022.